The Pharmacokinetics/Pharmacodynamics and Neurotoxicity of Tigecycline Intraventricular Injection for the Treatment of Extensively Drug-Resistant Acinetobacter baumannii Intracranial Infection
Qi Huang,Xingwen Zhang,Aijun Jia,Qi Huang,Yu Jiang,Liangyi Xie
DOI: https://doi.org/10.2147/IDR.S377772
2022-08-24
Infection and Drug Resistance
Abstract:Qi Huang, 1 Xingwen Zhang, 2 Aijun Jia, 2 Qi Huang, 3 Yu Jiang, 4 Liangyi Xie 5 1 Department of Pharmacy, Hunan Provincial People's Hospital (The first-affiliated hospital of Hunan normal university), Changsha, People's Republic of China; 2 Emergency Intensive Care Unit, Hunan Provincial People's Hospital (The first-affiliated hospital of Hunan normal university), Changsha, People's Republic of China; 3 Department of Pharmacy, Xiangya Hospital, Central South University, Changsha, People's Republic of China; 4 Institute of Emergency Medicine, Hunan Provincial People's Hospital (The first-affiliated hospital of Hunan normal university), Changsha, People's Republic of China; 5 Department of Laboratory Medicine, Hunan Provincial People's Hospital (The first-affiliated hospital of Hunan normal university), Changsha, People's Republic of China Correspondence: Qi Huang, Hunan Provincial People's Hospital (The first-affiliated hospital of Hunan normal university), Jiefangxi Road N.61, Changsha, Hunan, People's Republic of China, Tel +86-731-81866105, Email Objective: This study aimed to provide feasible suggestions for intraventricular injection of tigecycline to treat intractable Acinetobacter baumannii intracranial infections by studying its pharmacokinetics/pharmacodynamics and neurotoxicity. Methods: A simple and reliable two-dimensional high-performance liquid chromatography (2D-HPLC) method was used to determine tigecycline concentration. The pharmacokinetics (PK) of tigecycline in cerebrospinal fluid (CSF) was investigated by performing therapeutic drug monitoring (TDM). The pharmacodynamics (PD) of tigecycline was evaluated by its minimum inhibitory concentration (MIC) against XDR A. baumannii . CCK8 assay was used to evaluate the cytotoxicity of different concentrations of tigecycline effect on PC12 cells, and apoptosis assay was analyzed by flow cytometry. Results: Tigecycline retention time in 2D-HPLC was 7.636 min. The lower limit of quantitation (LLOQ) was 0.1mg/L, which met the requirements of concentration determination for TDM. The MIC 50 and MIC 90 values of tigecycline for A. baumannii were 2 and 4 mg/L, respectively. After a dose of 5mg tigecycline, Cmax in CSF was 37.894 mg/L which was high above the MIC values. The t 1/2 of tigecycline was estimated to be 2.73 hours. Tigecycline significantly decreased cell viability as assessed and induced apoptosis of the PC12 cell. The IC 50 value of PC12 cells treated with tigecycline was about 51.35 mg/L. Conclusion: Intraventricular injection of tigecycline is a promising method for treating XDR A. baumannii intracranial infection. Since a high concentration of tigecycline in CSF may have potential neurotoxicity, and the t 1/2 was short, giving small doses of less than 5 mg at least twice a day may be safer and more effective. Intraventricular injection of tigecycline must be selected cautiously and best carried out under TDM. Keywords: tigecycline, intraventricular injection, XDR A. baumannii , intracranial infection, TDM Intracranial infection is a severe, rapidly progressing, refractory disease with high mortality. Due to the blood–brain barrier, most antibiotics cannot enter the central nervous system (CNS) to play an effective antibacterial role. In recent years, A. baumannii , associated with post-neurosurgical meningitis and ventriculitis, has increasingly been reported. 1–3 According to China Antimicrobial Surveillance Network (CHINET), the most frequent organism was A. baumannii (12.5%) in 3157 pathogenic bacteria from cerebrospinal fluid strains. 4 It poses severe challenges to the anti-infection treatment given the high disability and mortality rate and few sensitive antibiotics to choose from. About 80% of A. baumannii strains were resistant to imipenem and meropenem. The majority of resistant strains are only sensitive to tigecycline and polymyxin B. 4 However, intravenous tigecycline and polymyxin B have poor CSF penetration and cannot treat the intracranial infection. Intraventricular or intrathecal drug administration is a method that bypasses the blood–brain barrier and other mechanisms that limit drug distribution into the brain. 5 According to the International Consensus Guidelines for the Optimal Use of the Polymyxins, Colistin Methanesulfonate (CMS) is the preferred polymyxin for intraventricular or intrathecal administration. 6 CMS is not approved for sale in China. Polymyxin B is the only alternative for intraventricular or intrathecal administration. Pol -Abstract Truncated-
pharmacology & pharmacy,infectious diseases